Phase I/II trial of AST-VAC2 in patients with non-small cell lung cancer.

Trial Profile

Phase I/II trial of AST-VAC2 in patients with non-small cell lung cancer.

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs VAC 2 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2016 According to an Asterias Biotherapeutics media release, preparation of a regulatory dossier to support execution of this study is underway with submission to the UK Medicines and Healthcare Products Agency (MHRA) planned early in the first quarter of 2017.
    • 04 Nov 2016 According to Asterias media release, the company planned to initiate this trial in the first half of 2017.
    • 29 Mar 2016 According to Asterias media release, the company expected to begin enrollment in this study in early 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top